Braidwell LP Takes $15.66 Million Position in Kymera Therapeutics, Inc. $KYMR

Braidwell LP bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 276,692 shares of the company’s stock, valued at approximately $15,661,000.

Other hedge funds also recently made changes to their positions in the company. Federated Hermes Inc. bought a new position in Kymera Therapeutics during the third quarter valued at approximately $31,622,000. China Universal Asset Management Co. Ltd. increased its stake in Kymera Therapeutics by 77.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock worth $1,007,000 after acquiring an additional 10,052 shares during the last quarter. Candriam S.C.A. increased its stake in Kymera Therapeutics by 24.4% in the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock worth $10,847,000 after acquiring an additional 37,536 shares during the last quarter. Frontier Capital Management Co. LLC raised its holdings in shares of Kymera Therapeutics by 272.7% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after acquiring an additional 359,847 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Kymera Therapeutics by 26.3% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after acquiring an additional 22,392 shares in the last quarter.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $79.03 on Friday. The firm has a market capitalization of $6.45 billion, a PE ratio of -21.48 and a beta of 2.20. The stock’s fifty day moving average is $79.21 and its 200 day moving average is $68.32. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same period in the previous year, the firm earned ($0.88) earnings per share. The firm’s quarterly revenue was down 60.8% compared to the same quarter last year. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In related news, insider Jared Gollob sold 4,895 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total value of $417,543.50. Following the sale, the insider directly owned 117,134 shares of the company’s stock, valued at $9,991,530.20. This represents a 4.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Bruce N. Jacobs sold 4,895 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total transaction of $417,543.50. Following the completion of the sale, the chief financial officer directly owned 232,588 shares of the company’s stock, valued at approximately $19,839,756.40. The trade was a 2.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 196,561 shares of company stock worth $17,097,428. 16.01% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KYMR shares. Oppenheimer boosted their price target on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Piper Sandler lifted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Truist Financial boosted their target price on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Citigroup upped their target price on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.